Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
1.
Ann Biol Clin (Paris) ; 79(6): 535-549, 2021 12 01.
Article in French | MEDLINE | ID: covidwho-1599850

ABSTRACT

During the first wave of Covid-19 in France, in spring 2020, healthcare institution's laboratory had to adapt itself quickly to the growing demand for emergency biology, in particular by reorganizing their POCT analyzers: redeployment of analyzers and/or new installations. In order to analyze this management, a subgroup of 15 hospital biologists from the SFBC Working Group "Biochemical markers of Covid-19" sent, in fall 2020, an on-line survey to French hospital laboratories using POCT. Answers analysis (n = 86) shows a territorial disparity related to the severity of the first wave: increased activity essentially in red zones, management of unexpected situations, training of additional nursing staff for 40 % of the laboratories... The survey also showed simplification of aspects related to accreditation those periods of health crisis. An additional survey, carried out in the spring of 2021, showed good overall satisfaction of the healthcare services (n = 139) concerning the services provided by biology in the POCT sector. Because of their great adaptation capacity, the laboratories and their POCT-teams have played a key role in the management of the first wave of Covid-19 in France. However, the success of these organizations requires an essential collaboration between laboratories and healthcare services. The results of this survey are fundamental in the context of the prolongation of the pandemia throughout the world with a POCT sector appearing to be growing.


Subject(s)
COVID-19 , Laboratories, Hospital , Accreditation , France , Humans , SARS-CoV-2
2.
Ann Biol Clin (Paris) ; 78(5): 499-518, 2020 10 01.
Article in French | MEDLINE | ID: covidwho-836031

ABSTRACT

The French society of clinical biology "Biochemical markers of COVID-19" has set up a working group with the primary aim of reviewing, analyzing and monitoring the evolution of biological prescriptions according to the patient's care path and to look for markers of progression and severity of the disease. This study covers all public and private sectors of medical biology located in metropolitan and overseas France and also extends to the French-speaking world. This article presents the testimonies and data obtained for the "Overseas and French-speaking countries" sub-working group made up of 45 volunteer correspondents, located in 20 regions of the world. In view of the delayed spread of the SARS-CoV-2 virus, the overseas regions and the French-speaking regions have benefited from feedback from the first territories confronted with COVID-19. Thus, the entry of the virus or its spread in epidemic form could be avoided, thanks to the rapid closure of borders. The overseas territories depend very strongly on air and/or sea links with the metropolis or with the neighboring continent. The isolation of these countries is responsible for reagent supply difficulties and has necessitated emergency orders and the establishment of stocks lasting several months, in order to avoid shortages and maintain adequate patient care. In addition, in countries located in tropical or intertropical zones, the diagnosis of COVID-19 is complicated by the presence of various zoonoses (dengue, Zika, malaria, leptospirosis, etc.).


Subject(s)
Clinical Laboratory Services , Coronavirus Infections/diagnosis , Coronavirus Infections/epidemiology , Coronavirus Infections/therapy , Global Health/statistics & numerical data , Pneumonia, Viral/diagnosis , Pneumonia, Viral/epidemiology , Pneumonia, Viral/therapy , Travel Medicine/organization & administration , Adult , Africa/epidemiology , Aged , Aged, 80 and over , Belgium/epidemiology , Betacoronavirus/physiology , Biomarkers/analysis , Biomarkers/blood , COVID-19 , Cambodia/epidemiology , Child , Clinical Laboratory Services/organization & administration , Clinical Laboratory Services/statistics & numerical data , Contact Tracing/methods , Contact Tracing/statistics & numerical data , Coronavirus Infections/transmission , Diagnosis, Differential , Female , France/epidemiology , Hospitalization/statistics & numerical data , Humans , Infant, Newborn , Islands/epidemiology , Language , Laos/epidemiology , Louisiana/epidemiology , Male , Medical Laboratory Personnel/organization & administration , Medical Laboratory Personnel/statistics & numerical data , Middle Aged , Pandemics , Pneumonia, Viral/transmission , Retrospective Studies , SARS-CoV-2 , Surveys and Questionnaires , Survival Analysis , Travel Medicine/methods , Travel Medicine/statistics & numerical data , Travel-Related Illness , Tropical Climate , Tropical Medicine/methods , Tropical Medicine/organization & administration , Tropical Medicine/statistics & numerical data , Vietnam/epidemiology
3.
Ann Biol Clin (Paris) ; 78(3): 269-277, 2020 06 01.
Article in French | MEDLINE | ID: covidwho-608309

ABSTRACT

The SARS-CoV-2 virus is responsible for an epidemic disease called COVID-19, which was initially evidenced in Wuhan, China, and spread very rapidly in China and around the world. In France, the first isolated case seems now to be reported in December 2019, stage 3 of the COVID-19 epidemic was triggered on March 14th, the start of the planned containment exit from May 11th. Healthcare services have faced a large influx of patients who may be beyond their capacity to receive and care, particularly in the Large-East and Ile-de-France regions. Some patients show an evolution of the disease never observed before with other coronaviruses and develop in a few days a very important inflammatory reaction, which can lead to death of patients. A working group of the French Society of Clinical Biology (SFBC) was set up with the objective of providing updated information on the current status of the biological prescriptions (focusing on biochemistry ones) and their evolution during the epidemic, and of analyzing the biological parameters associated with comorbidities and patient evolution in order to link biological results with medical events. The expanded working group covers all sectors of medical biology in France and extends to the French-speaking world: hospital sectors (CHU and CH, Army Training Hospitals) and the private sector opening a field of view on the biological situation in establishments for dependent elderly, social establishments and clinical medical institutions. The purpose of this article is the presentation of this working group and its immediate and future actions.


Subject(s)
Betacoronavirus , Biochemistry/organization & administration , Biomarkers/analysis , Clinical Laboratory Services/organization & administration , Coronavirus Infections/diagnosis , Pneumonia, Viral/diagnosis , Societies, Scientific/organization & administration , Betacoronavirus/isolation & purification , Betacoronavirus/pathogenicity , Biochemistry/standards , Biomarkers/blood , COVID-19 , Clinical Laboratory Services/standards , Community Networks/organization & administration , Community Networks/standards , Community Networks/trends , Coronavirus Infections/blood , Coronavirus Infections/epidemiology , Disease Outbreaks , France/epidemiology , History, 21st Century , Humans , Intersectoral Collaboration , Pandemics , Pneumonia, Viral/blood , Pneumonia, Viral/epidemiology , Professional Practice/organization & administration , Professional Practice/standards , Professional Practice/trends , SARS-CoV-2 , Societies, Scientific/standards , Videoconferencing/organization & administration , Videoconferencing/standards
SELECTION OF CITATIONS
SEARCH DETAIL